Bridging the Gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancerG Grazia, Federica Martorana, Chiara Conti et al.|Critical Reviews in Oncology/Hematology|2025Cited by 5
REThinking the role of the RET oncogene in breast cancerG Grazia, Paolo Vigneri, Federica Martorana et al.|Frontiers in Oncology|2024Cited by 3
Effectiveness comparison of palbociclib, ribociclib and abemaciclib in patients with HR+/HER2- aBC: Updated results from the real-world, Italian study PALMARES-2.Claudio Vernieri, Maria Vittoria Dieci, Roberta Caputo et al.|Journal of Clinical Oncology|2025Cited by 1
Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysisFrancesco Schettini, Daniele Generali, Sabrina Nucera et al.|JNCI Cancer Spectrum|2025Cited by 1
Abstract P1-10-14: Bridging the gap between real-world studies (RWSs) and randomized controlled trials (RCTs) of 1st-line palbociclib+aromatase inhibitors (P+AI) in hormone receptor-positive(HR+)/HER2-negative(-) metastatic breast cancer (mBC)Daniele Generali, Giuseppe Curigliano, Sabrina Nucera et al.|Clinical Cancer Research|2025Cited by 0